Xencor, Inc.

Since 1997, Xencor has built the most powerful protein engineering technology platform in the biotechnology industry. Its versatility is evidenced by our success in developing two classes of superior protein drug candidates: XmAb antibody therapeutics and XPro protein therapeutics. Because we can engineer the affinity and specificity of protein-protein interactions, we are also generating entirely new therapeutic mechanisms of action. In collaboration with our partners including leading biotechnology company Genentech and pharmaceutical company Eli Lilly we are selectively designing next-generation protein drug candidates with improved selectivity, efficacy and safety. Our internal pipeline of antibodies for cancer and protein therapeutics for inflammation and autoimmune disease address well understood and validated targets with potent new molecules. More than 40 talented scientists and the 8 industry veterans who make up our management team are working diligently to bring these drugs to the clinic and to deliver on the promise of protein-based medicines.